Abstract: Hyperthermic intraperitoneal chemotherapy （HIPEC）， a promising treatment modality for advanced gastric cancer， colorectal cancer， ovarian cancer and other abdominal malignant tumors with ascites， has been widely used in the clinic. The HIPEC supplemented by immunotherapy with intraperitoneal perfusion of interleukin2， interferon and other immune agents appears to be a feasible and effective treatment for malignant ascites. The combination of HIPEC and immunotherapy can be regarded as a scientific and comprehensive treatment. This review will focus on the clinical applications of HIPEC plus immunotherapy for the treatment of malignant ascites.